Mercilon Adverse Reactions

Description of selected adverse reactions: An increased risk of arterial and venous thrombotic and thromboembolic events, including myocardial infarction, stroke, transient ischaemic attacks, venous thrombosis and pulmonary embolism has been observed in women using CHCs, which are discussed in more detail in Warnings.
As with all COCs, changes in vaginal bleeding patterns may occur, especially during the first months of use. These may include changes in bleeding frequency (absent, less frequent, more frequent or continuous), intensity (reduced or increased) or duration.
Possibly related undesirable effects that have been reported in users of Mercilon or COC users in general are listed in the following table¹. All ADRs are listed by system organ class and frequency: common (≥1/100), uncommon (≥1/1000 to <1/100) and rare (<1/1000). (See Table 3.)

Click on icon to see table/diagram/image

A number of undesirable effects have been reported in women using COCs are discussed in detail in Warnings. These include: hypertension; hormone-dependent tumours (e.g. liver tumours, breast cancer); chloasma.
Interactions: Breakthrough bleeding and/or contraceptive failure may result from interactions of other drugs (enzyme inducers) with oral contraceptives (see Interactions).
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the local reporting system.